- Previous Close
0.4500 - Open
0.4100 - Bid 0.3800 x --
- Ask 0.4500 x --
- Day's Range
0.4020 - 0.4500 - 52 Week Range
0.3750 - 4.4890 - Volume
4,021,197 - Avg. Volume
6,239,310 - Market Cap (intraday)
1.685M - Beta (5Y Monthly) 0.10
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
www.valirx.comRecent News: VAL.L
View MorePerformance Overview: VAL.L
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VAL.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VAL.L
View MoreValuation Measures
Market Cap
1.55M
Enterprise Value
761.39k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
50.48
Price/Book (mrq)
0.40
Enterprise Value/Revenue
79.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-35.98%
Return on Equity (ttm)
-55.38%
Revenue (ttm)
9.6k
Net Income Avi to Common (ttm)
-1.97M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
809.15k
Total Debt/Equity (mrq)
0.49%
Levered Free Cash Flow (ttm)
-953.49k